Your browser doesn't support javascript.
loading
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
Achiron, Anat; Mandel, Mathilda; Dreyer-Alster, Sapir; Harari, Gil; Magalashvili, David; Sonis, Polina; Dolev, Mark; Menascu, Shay; Flechter, Shlomo; Falb, Rina; Gurevich, Michael.
Afiliação
  • Achiron A; Multiple Sclerosis Center, Sheba Medical Center and The Laura Schwarz-Kipp Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Israel, 2 Derech Sheba, Ramat-Gann, 52621, Israel.
  • Mandel M; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
  • Dreyer-Alster S; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
  • Harari G; School of Public Health, University of Haifa, Israel.
  • Magalashvili D; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
  • Sonis P; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
  • Dolev M; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
  • Menascu S; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, and Sackler School of Medicine, Tel-Aviv University, Israel.
  • Flechter S; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
  • Falb R; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
  • Gurevich M; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, and Sackler School of Medicine, Tel-Aviv University, Israel.
Ther Adv Neurol Disord ; 14: 17562864211012835, 2021.
Article em En | MEDLINE | ID: mdl-34035836

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Ther Adv Neurol Disord Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Israel

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Ther Adv Neurol Disord Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Israel